Bacterial resistance to antibiotics and associated factors in two hospital centers in Lebanon from January 2017 to June 2017

Salim SALLOUM b, Michel TAWK a,*, Loubna TAYYARA c

a Internal Medicine Resident, Lebanese University, Rouphael Abou Jawde Street, Anwar Sello Building, Third Floor, Zalka, Lebanon
b Internal Medicine Resident, Lebanese University, Lebanon
c Doctor of Internal and Pulmonary Medicine, Master Degree in Epidemiology and Biostatistics, Research Carried Out in Lebanese Hospital Geitaoui, Makassed General Hospital, Lebanon

ARTICLE INFO

Article history:
Received 10 January 2020
Accepted 5 February 2020
Available online 12 February 2020

KEYWORDS:
Antibiotic resistance
Multi-drug resistance
Gram-positive bacteria
Gram-negative bacteria
Lebanon

SUMMARY

General presentation: Resistance of bacteria to antibiotics is a universal problem. With the increase in the rate of resistance, knowledge of susceptibility patterns is essential to guide antimicrobial therapy. In Lebanon, many studies investigated this subject.

Objectives: Determine the rate of multidrug and extremely drug-resistant bacteria as well as the patterns of resistance and the factors associated with this resistance.

Materials and methods: A cross-sectional study was performed using the cultures from the labs of two university hospitals in Lebanon. Bacteria were divided into four groups: sensitive, multidrug-, extremely- and pan-drug resistant. Patient information was obtained from the medical records. Using the SPSS software for Windows, version 20 (IBM, Armonk, USA), the frequency of the bacteria, their susceptibilities and the association of resistance with seven potential factors (age, gender, diabetes mellitus, cancer, chronic kidney disease, dialysis, previous hospitalization) were studied.

Results: The frequency of resistance was 53.7% (39.9% multidrug-resistant and 13.8% extremely drug-resistant). Escherichia coli strains were mostly susceptible to carbapenems and tigecycline; and nitrofurantoin and fosfomycin in urine. Pseudomonas and Acinetobacter species were mostly sensitive to colistin. Klebsiella species were mostly susceptible to amikacin and carbapenems. MRSA rates were 34.8%. Association was seen between the resistant bacteria and older age, chronic kidney disease, dialysis, previous hospitalization and previous hospitalization.

Conclusion: Resistance of bacteria to drugs in Lebanon is increasing. Significant association is seen between these bacteria and older age, chronic kidney disease, dialysis, and previous hospitalization.

© 2020 The Authors. Published by Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Like all living creatures, bacteria try to survive. They do so by adapting to adverse environmental conditions and by
developing resistance to poisons they are exposed to, mainly antibiotics. Some bacteria are naturally resistant to a drug because of the absent target or entry site for the drug and such resistance is known as intrinsic. In other cases, the process is acquired.

Resistant and multi-drug resistant strains are predictive of increased hospital costs in comparison with non-resistant strains. With the increase of resistant bacteria, susceptibility testing is increasingly important to direct the treatment of infected patients. However, isolation of the etiological agent is not always possible, and even when possible it takes time to obtain results. Therefore, initial antibiotic therapy is typically empiric. Rational empiric prescribing depends on knowledge of patterns of antibiotic resistance obtained through regional and national epidemiological studies of bacterial isolates from patients [1].

In Lebanon, many studies have investigated the patterns of resistance in order to guide antimicrobial therapy. A study published in 2016 of antimicrobial resistance in Lebanese hospitals provided population-specific data that were valuable in guiding antimicrobial use in this country. It concluded that antimicrobial resistance was becoming a major threat in Lebanon [2]. However, since the patterns of resistance are ever-changing, new data should be continuously brought to light to help guiding the treatment.

The primary objective of this study was to determine the incidence rate of multi-drug-resistant bacteria among the positive laboratory cultures during the period from January 2017 to June 2017, in Makassed General Hospital and Lebanese Hospital Geitaoui. Secondary objectives were to determine antibiotic susceptibility patterns of bacteria and to determine potential risk factors associated with resistance, including patient age and gender, and the presence of diabetes mellitus, cancer, chronic kidney disease, dialysis and previous hospitalization.

Methods

A cross-sectional analytical laboratory-based study was conducted in the Bacteriology laboratories of two hospitals (Makassed General Hospital, Lebanese Hospital Geitaoui) from January 2017 to June 2017. These hospitals serve mainly the population of Beirut as well as other parts of Lebanon where cases are referred to these university hospitals. All cultures with positive growth for bacteria were collected. The laboratories use the disc diffusion technique to determine antimicrobial susceptibility.

The following cultures were excluded from the study:

- Cultures with incomplete antibiogram (that is, an antibiogram that cannot be used to define multidrug resistance) or no antibiogram.
- Duplicates from the same patient.

For each culture included in the study, the following patient information were collected from their medical records: age, sex, presence of co-morbidities (diabetes mellitus, chronic kidney disease, dialysis, cancer) and history of hospitalization in the last three months.

Bacteria were divided in four groups: antibiotic-sensitive bacteria, multidrug resistant bacteria (MDR) (defined as non-susceptible to at least one agent in three or more classes of antimicrobial drugs among those that are available at the time of use of the definition and that are regarded as potentially effective against the respective pathogen), extensive drug resistant bacteria (XDR) (resistant to all but one or two classes of antimicrobial agents) and pan-drug resistant bacteria (resistant to all the antimicrobial classes) [3].

Using SPSS software for Windows, version 20 (IBM, Armonk, USA), we determined the distribution of different isolates frequencies as well as the frequency of their susceptibility. The existence of a relationship between different factors and the incidence of drug-resistant bacteria was determined using the Chi-square test. A $P$ value of $< 0.05$ was considered significant.

Results

A total of 1437 cultures were collected from the hospitals. The most frequently cultured organism was *Escherichia coli*, accounting for 40.8% of the cultures, followed by *Pseudomonas* spp. (11.6%), *Klebsiella* spp. (10%), *Acinetobacter* spp. (7.7%), coagulase-negative staphylococci (SCN) (6.2%), *Proteus mirabilis* (5.2%) and *Staphylococcus aureus* (4.6%) (Table I). 46.3% of bacteria were antibiotic-sensitive. The frequencies of MDR and XDR bacteria were 39.9% and 13.8%, respectively. The antibiograms of the most common organisms are shown in
Table II. Most strains of *E. coli* were antibiotic-resistant (59.6%). Resistance rates were highest to ampicillin (76.5%) followed by amoxicillin + clavulanate (49%), ciprofloxacin (48%) and trimethoprim-sulfamethoxazole (TMP-SMX) (47.8%). Minimal resistance was observed to carbapenems and tigecycline as well as fosfomycin and nitrofurantoin for the urine specimen. For *Pseudomonas* spp., most isolates (66.5%) were deemed antibiotic-sensitive, with MDR and XDR strains accounting for 8.4% and 25.1%, respectively. Resistance was minimal to colistin (0.6%), but over one third of isolates were resistant to gentamicin (34.7%) and ciprofloxacin (34.1%).

Among *Klebsiella* spp. most isolates (66.5%) were deemed antibiotic-sensitive, with MDR and XDR strains accounting for 8.4% and 25.1%, respectively. Resistance was minimal to colistin (0.6%), but over one third of isolates were resistant to gentamicin (34.7%) and ciprofloxacin (34.1%).

For *S. aureus*, the resistance rate was 31.8% (MDR 28.8% and XDR 3%). The percentage of meticillin-resistant *S. aureus* (MRSA) was 34.8%. No resistance was seen against teicoplanin and minimal resistance was observed for linezolid (1.5%) and vancomycin (3%) (Table III).

Factors investigated for an association with antibiotic resistance are shown in Table IV. There was a significant association between older age (≥65 years) and bacterial resistance to antibiotics \( P = 0.001 \). Patients with chronic kidney disease, whether receiving dialysis or not, tended to have more drug resistant bacterial infections than people with normal kidney function. The prevalence of chronic kidney disease is higher in older patients, making it possible that age is the main factor determining the likelihood of resistance. When the population was divided in two groups according to their age, the number of antibiotic-resistant cases almost doubles when CKD is present in both age groups showing that age is not the main factor determining the likelihood of resistance (Table V). Previous hospitalization within the preceding three months was the strongest risk factor for having antibiotic-resistant bacteria. In addition, Table VI shows that dialysis was a risk factor for antibiotic resistance, even in the absence of previous hospitalization.

### Discussion

Up to 59.6% of the *E. coli* strains were resistant to at least three antimicrobial classes. This number is significantly different from that of European countries, where one study showed that these strains represent only 12.3% of the cases [4]. TMP-SMX should be avoided as empirical treatment for urinary

| Antibiotic | *Escherichia coli* | *Pseudomonas* spp. | *Klebsiella* spp. | *Acinetobacter baumanii* |
|------------|-------------------|--------------------|-------------------|-------------------------|
| Ampicillin | 76.5% (448)       | -                  | 39.6% (57)        | -                       |
| Amoxicillin + clavulanate | 49.0% (287) | -                  | -                  | -                       |
| Piperacillin + tazobactam | 18.4% (108) | 31.1% (52)         | 18.8% (27)        | 91.8% (101)             |
| Cefoxitine | 31.9% (187)       | -                  | 29.2% (42)        | -                       |
| Cefuroxime | 47.1% (276)       | -                  | 35.4% (51)        | -                       |
| Ceftriaxone | 45.6% (267)       | -                  | 34.0% (49)        | -                       |
| Ceftazidime | 42.8% (251)       | 25.1% (42)         | 34.7% (50)        | 90.9% (100)             |
| Cefepime | 37.7% (221)       | 28.7% (48)         | 28.5% (41)        | 89.1% (98)              |
| Imipenem | 1.4% (8)          | 31.7% (53)         | 1.4% (2)          | 90.9% (100)             |
| Ertapenem | 2.7% (16)         | -                  | 2.8% (4)          | -                       |
| Gentamicin | 20.3% (119)       | 34.7% (58)         | 20.1% (29)        | 88.2% (97)              |
| Amikacin | 5.1% (30)         | 26.9% (45)         | 0.0% (0)          | 90.9% (100)             |
| Tobramycin | -                | 22.8% (38)         | -                 | -                       |
| Ciprofloxacin | 48% (281)        | 34.1% (57)         | 31.2% (45)        | 92.7% (102)             |
| Tigecycline | 0.7% (4)         | -                  | 6.2% (9)          | 43.6% (48)              |
| Aztreonam | 41.5% (243)       | 21.6% (36)         | 34% (49)          | -                       |
| TMP-SMX | 47.8% (280)       | -                  | 45.8% (66)        | 93.6% (103)             |
| Fosfomycin (urine) | 3.4% (16)      | -                  | 6.4% (6)          | -                       |
| Nitrofurantoine (urine) | 8.6% (41)    | -                  | 52.1% (49)        | -                       |
| Colistin | -                | 0.6% (1)           | -                 | 0.0% (0)                |

The percentages represent the frequency of resistance. The numbers in brackets represent the count.
tract infections (UTI) since the resistance is around 47.8% (>20% as upper limit of acceptable resistance by Infectious Disease Society of America) [5]. This number does not differ significantly from that of 1994, when Araj et al. described 42% resistance to TMP-SMX [6]. Resistance to ciprofloxacin in our study was the same rate as reported by Chamoun et al., and a major increase when compared to 1994 when resistance to norfloxacin and pefloxacin were only 2% and 8% respectively [2,6]. This could be due to the extensive and uncontrolled use of these agents in treatment, and/or non-compliance of patients in completing full courses of treatment.

In Europe in 2018 only 11.6% of pseudomonas isolates were reported to be antibiotic-resistant [4], a far lower rate than in our study. The most common resistances in our study were to gentamicin (34.7%) and ciprofloxacin (34.1%), these rates also described 42% resistance to TMP-SMX [5]. Resistance to ciprofloxacin in our study was the same rate as reported by Chamoun et al., and a major increase when compared to 1994 when resistance to norfloxacin and pefloxacin were only 2% and 8% respectively [2,6]. This could be due to the extensive and uncontrolled use of these agents in treatment, and/or non-compliance of patients in completing full courses of treatment.

In Europe in 2018 only 11.6% of pseudomonas isolates were reported to be antibiotic-resistant [4], a far lower rate than in our study. The most common resistances in our study were to gentamicin (34.7%) and ciprofloxacin (34.1%), these rates also described 42% resistance to TMP-SMX [5]. Resistance to ciprofloxacin in our study was the same rate as reported by Chamoun et al., and a major increase when compared to 1994 when resistance to norfloxacin and pefloxacin were only 2% and 8% respectively [2,6]. This could be due to the extensive and uncontrolled use of these agents in treatment, and/or non-compliance of patients in completing full courses of treatment.

In Europe in 2018 only 11.6% of pseudomonas isolates were reported to be antibiotic-resistant [4], a far lower rate than in our study. The most common resistances in our study were to gentamicin (34.7%) and ciprofloxacin (34.1%), these rates also described 42% resistance to TMP-SMX [5]. Resistance to ciprofloxacin in our study was the same rate as reported by Chamoun et al., and a major increase when compared to 1994 when resistance to norfloxacin and pefloxacin were only 2% and 8% respectively [2,6]. This could be due to the extensive and uncontrolled use of these agents in treatment, and/or non-compliance of patients in completing full courses of treatment.

In Europe in 2018 only 11.6% of pseudomonas isolates were reported to be antibiotic-resistant [4], a far lower rate than in our study. The most common resistances in our study were to gentamicin (34.7%) and ciprofloxacin (34.1%), these rates also described 42% resistance to TMP-SMX [5]. Resistance to ciprofloxacin in our study was the same rate as reported by Chamoun et al., and a major increase when compared to 1994 when resistance to norfloxacin and pefloxacin were only 2% and 8% respectively [2,6]. This could be due to the extensive and uncontrolled use of these agents in treatment, and/or non-compliance of patients in completing full courses of treatment.

A. baumannii was the most resistant bacterium with 92.7% of strains being antibiotic-resistant, and 89.1% being XDR. This is markedly different to the situation in Europe, where 45.7% of strains were antibiotic-resistant [4]. It is notable that in 1994 Araj et al. found sensitivity rates of 90% to imipenem and 74% to quinolones [6].

The proportion of S. aureus isolates that were MRSA (34.8%) represents an increase from previous reports of 27.1% in 2013 and 18% in 1994 [2,6]. In Europe 2018, MRSA represented only 16.4% of isolates [4].

We know of no local studies that have previously investigated the association of age with antibiotic resistance. Data from other countries are conflicting. Wolfe et al. reported that age was significantly associated with resistance to antibiotics. However other studies have reported that age is not a factor in determining antibiotic resistance in patients with febrile UTI specifically, or in patients generally. An Iranian study also found no significant association between age and the likelihood of having extended-spectrum beta-lactamase (ESBL)-producing bacteria.

Several studies have investigated the relationship between gender and antibiotic resistance. An Iranian study found no association between gender and ESBL resistance [10], and an American study showed no difference in the susceptibility patterns of E. coli causing UTI in men and women [11]. However other studies have reported that age is not a factor in determining antibiotic resistance in patients with febrile UTI specifically, or in patients generally [8,9]. An Iranian study also found no significant association between age and the likelihood of having extended-spectrum beta-lactamase (ESBL)-producing bacteria.

Multiple studies have addressed the association of CKD and dialysis with resistance. Guobin-Su et al. found that poorer kidney function at the time of hospital admission is associated with higher probabilities of having multidrug resistant organisms [13]. Majeed et al. found that all bacterial isolates in patients with CKD were more virulent than isolates from those without kidney disease [14].

We found that patients with previous hospitalizations during the past three months have more resistant bacterial strains than those without such hospitalization. The possibility of the age of the patient being a confounding factor was eliminated by rechecking the association between previous hospitalization and resistance in each age group. with the same association seen in both groups. Many studies have addressed this issue. For

### Table IV

| Susceptibility | χ² | p |
|---------------|----|---|
| Sensitive | Resistant |    |
| Age < 65 years | 262 | 266 | 10.591 | 0.001* |
| Age > 65 years | 269 | 400 | 1.431 | 0.232 |
| Gender Males | 237 | 322 | 3.414 | 0.065 |
| Gender Females | 292 | 345 | 1.536 | 0.215 |
| Diabetes Yes | 115 | 185 | 4.826 | 0.028 |
| Diabetes No | 354 | 441 | 4.089 | 0.001 |
| CKD Yes | 39 | 78 | 24.2 | 10^-6*** |
| CKD No | 430 | 548 | 6.062 | 0.013 |
| Dialysis Yes | 8 | 34 | 20.1 | 10^-6*** |
| Dialysis No | 461 | 592 | 6.184 | 0.013 |
| Hospitalization Yes | 118 | 235 | 24.2 | 10^-6*** |
| Hospitalization No | 404 | 421 | 6.062 | 0.013 |

*ns: non-significant; *: P < 0.05; **: P < 0.001.

### Table V

| Susceptibility | χ² | p |
|---------------|----|---|
| Sensitive | Resistant |    |
| Age < 64 | CKD | 8 | 19 | 3.644 | 0.056 |
| No CKD | 214 | 227 | 1.078 | 0.299 |
| Age ≥ 65 | CKD | 31 | 59 | 3.644 | 0.056 |
| No CKD | 216 | 321 | 1.078 | 0.299 |

*ns: non-significant; *: P < 0.05; **: P < 0.001.

### Table VI

| Susceptibility | χ² | Fischer’s exact test |
|---------------|----|---------------------|
| Sensitive | Resistant |    |
| Hospitalized | Dialysis | 4 | 19 | 2.727 | 0.099ns |
| No Dialysis | 112 | 216 | 5.447 | 0.020* |
| Not Hospitalized | No Dialysis | 349 | 376 | 5.447 | 0.020* |

*ns: non-significant; *: P < 0.05; **: P < 0.001.
example, Toubes et al. found that previous hospitalization within 30 days was associated with resistance (P value of 0.04) [15]. Tenny et al. also reported that previous hospitalization was one of the most probable risk factors for MDR pathogens, which supports our results [16].

In conclusion, we found that MDR bacteria represented 39.9% of cultures, and XDR bacteria 13.8%. Older age, chronic kidney disease, dialysis and previous hospitalization within the past three months prior to the culture dates were factors associated with resistance. Cancer, diabetes mellitus and gender were not found to be associated with resistance. We recommend yearly surveillance of patterns of resistance to guide the empiric prescribing of antibiotics.

Declaration of interests
None.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

[1] Kyungwon L, Ki HP, Seok HJ, Hwan SL, Jong HS, Dongeon Y, et al. Further increase of vancomycin-resistant Enterococcus faecium, amikacin- and fluoroquinolone-resistant Klebsiella pneumoniae, and imipenem-resistant Acinetobacter spp. in Korea: 2003 KON-SAR surveillance. Yonsei Med J 2006;47:43–54.

[2] Chamoun K, Farah M, Araj G, Daoud Z, Moughnieh R, Salameh P, et al. Surveillance of antimicrobial resistance in Lebanese hospitals: retrospective nationwide compiled data. Int J Infect Dis 2016;46:64–70.

[3] Falagas M, Karageorgopoulos D. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008;46:1121–2.

[4] European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe 2018. Stockholm: ECDC; 2019.

[5] Gupta K, Hooton T, Nabar KG, Wullit B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious diseases society of America and the European society for microbiology and infectious diseases. Clin Infect Dis 2011;52:e103–20.

[6] Araj G, Uwaydah M, Alami S. Antimicrobial susceptibility patterns of bacterial isolates at the American University Medical Center in Lebanon. Diagn Microbiol Infect Dis 1994;20:151–8.

[7] Wolfe C, Cohen B, Larson E. Prevalence and risk factors for antibiotic-resistant community-associated bloodstream infections. J Infect Public Health 2014;7:224–32.

[8] Lee DS, Choe HS, Kim HY, Yoo JM, Bae WJ, Chu YH, et al. Role of age and sex in determining antibiotic resistance in febrile urinary tract infections. Int J Infect Dis 2016;51:89–96.

[9] Kolozsvári LR, Könya J, Paget J, Schellevis FG, Sándor J, József G, et al. Patient-related factors, antibiotic prescribing and antimicrobial resistance of the commensal Staphylococcus aureus and Streptococcus pneumoniae in a healthy population - Hungarian results of the APRES study. BMC Infect Dis 2019;19:253–61.

[10] Sharif M, Soltani B, Moravveji A, Erami M, Soltani N. Prevalence and risk factors associated with extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae isolates in hospitalized patients in Kashan (Iran). Electron Physician 2016;8:2081–7.

[11] McGregor JC, Elman MR, Bearden DT, Smith DH. Sex- and age-specific trends in antibiotic resistance pattern of Escherichia coli urinary isolates from outpatients. BMC Fam Pract 2013:14–25.

[12] den Heijer CD, Penders J, Donker GA, Bruggeman CA, Stobberingh EE. The importance of gender-stratified antibiotic resistance surveillance of unselected uropathogens: a Dutch nationwide extramural surveillance study. PLoS One 2013:8:e60497-e60503.

[13] Su G, Xu H, Riggi E, He Z, Lu L, Lindholm B, et al. Association of kidney function with infections by multidrug-resistant organisms: an electronic medical record analysis. Sci Rep 2018;8:13372–81.

[14] Majeed H, Aljanaby A. Antibiotic Susceptibility patterns and prevalence of some extended spectrum beta-lactamases genes in Gram-negative bacteria isolated from patients infected with urinary tract infections in Al-Najaf city, Iraq. Avicenna J Med Biotechnol 2019;11:192–201.

[15] Toubes E, Singh K, Yin D, Lyu R, Glick N, Russell L, et al. Risk factors for antibiotic-resistant infection and treatment outcomes among hospitalized patients transferred from long-term care facilities: does antimicrobial choice make a difference? Clin Infect Dis 2003;36:724–30.

[16] Tenny J, Hudson N, Alnifaidy H, Li T, Fung K. Risk factors for acquiring multidrug-resistant organisms in urinary tract infections: a systematic literature review. Saudi Pharm J 2018;26:678–84.